The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Abstract
Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Self-citationModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“Increasing evidence suggests that anti-VEGF therapy may increase the tendency of tumor cells to co-opt existing blood vessels, resulting in an invasive nonenhancing phenotype.(52-54) Unlike the Macdonald Criteria, which do not take into account progressive nonenhancing disease, the new response assessment will conside…”
BackgroundBevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Self-citationPàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Self-citationKreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Self-citationClinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,121
Self-citationWHO handbook for reporting results of cancer treatment
Sylvester, R. (1980) · Controlled Clinical Trials · doi:10.1016/0197-2456(80)90009-4 · Cited by 1,055
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902 · cited 1×
“The evaluation of treatment in high-grade gliomas currently relies either on the duration of patient survival or, more commonly in patients with recurrent disease, the radiographic response rate or progression-free survival (PFS).(3,4) In 1990, Macdonald et al(5) published criteria for response assessment in high-grad…”
BackgroundSelf-citationBrandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 840
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 801
Self-citationKumar, A. J., Leeds, N. E., Fuller, G. N., Van Tassel, P., Maor, M. H., Sawaya, R. E., & Levin, V. A. (2000) · Radiology · doi:10.1148/radiology.217.2.r00nv36377 · Cited by 669
Rubenstein, J. L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D. F., & Shuman, M. A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900102 · Cited by 509
Taal, W., Brandsma, D., de Bruin, H. G., Bromberg, J. E., Swaak‐Kragten, A. T., Sillevis Smitt, P. A. E., van Es, C. A., & van den Bent, M. J. (2008) · Cancer · doi:10.1002/cncr.23562 · Cited by 465
Self-citationMagnetic resonance spectroscopy of the brain: review of metabolites and clinical applications
Soares, D. P., & Law, M. (2009) · Clinical Radiology · doi:10.1016/j.crad.2008.07.002 · Cited by 459
Clinical Applications of PET in Brain Tumors
Chen, W. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037689 · Cited by 449
Lamborn, K. R., Yung, W. K. A., Chang, S. M., Wen, P. Y., Cloughesy, T. F., DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., Fink, K. L., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-062 · Cited by 421
Self-citationSorensen, A. G., Batchelor, T. T., Zhang, W.-T., Chen, P.-J., Yeo, P., Wang, M., Jennings, D., Wen, P. Y., Lahdenranta, J., Ancukiewicz, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0814 · Cited by 394
Self-citationImmediate post-radiotherapy changes in malignant glioma can mimic tumor progression
de Wit, M. C. Y., de Bruin, H. G., Eijkenboom, W., Sillevis Smitt, P. A. E., & van den Bent, M. J. (2004) · Neurology · doi:10.1212/01.wnl.0000133398.11870.9a · Cited by 357
Self-citationEarly necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
Chamberlain, M. C., Glantz, M. J., Chalmers, L., Van Horn, A., & Sloan, A. E. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9241-y · Cited by 343
Self-citationImmediate post-radiotherapy changes in malignant glioma can mimic tumor progression
Box, P. (2005) · Dkgest of the World Latest Medical Information · Cited by 299
Comparison of Diameter and Perimeter Methods for Tumor Volume Calculation
Sorensen, A. G., Patel, S., Harmath, C., Bridges, S., Synnott, J., Sievers, A., Yoon, Y.-H., Lee, E. J., Yang, M. C., Lewis, R. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.551 · Cited by 270
Self-citationCentral Nervous System Cancers
Nabors, L. B., Ammirati, M., Bierman, P. J., Brem, H., Butowski, N., Chamberlain, M. C., DeAngelis, L. M., Fenstermaker, R. A., Friedman, A., Gilbert, M. R., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0132 · Cited by 247
Self-citationNovel anti-angiogenic therapies for malignant gliomas
Norden, A. D., Drappatz, J., & Wen, P. Y. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70260-6 · Cited by 246
Self-citationEnd Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
van den Bent, M. J., Vogelbaum, M. A., Wen, P. Y., Macdonald, D. R., & Chang, S. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4998 · Cited by 240
Self-citationShah, G. D., Kesari, S., Xu, R., Batchelor, T. T., O'Neill, A. M., Hochberg, F. H., Levy, B., Bradshaw, J., & Wen, P. Y. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000529 · Cited by 195
Self-citationSorensen, A. G., Batchelor, T. T., Wen, P. Y., Zhang, W.-T., & Jain, R. K. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1204 · Cited by 192
Self-citationSmith, J. S., Cha, S., Mayo, M. C., McDermott, M. W., Parsa, A. T., Chang, S. M., Dillon, W. P., & Berger, M. S. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.103.3.0428 · Cited by 175
Self-citationBrain Tumor Imaging in Clinical Trials
Henson, J. W., Ulmer, S., & Harris, G. J. (2008) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0963 · Cited by 167
Advanced MRI of Adult Brain Tumors
Young, G. S. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.07.010 · Cited by 154
Galanis, E., Buckner, J. C., Maurer, M. J., Sykora, R., Castillo, R., Ballman, K. V., & Erickson, B. J. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-005 · Cited by 139
Self-citationAn exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
Norden, A. D., Drappatz, J., Muzikansky, A., David, K., Gerard, M., McNamara, M. B., Phan, P., Ross, A., Kesari, S., & Wen, P. Y. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9745-8 · Cited by 137
Self-citationClinical and radiographic features of peritumoral infarction following resection of glioblastoma
Ulmer, S., Braga, T. A., Barker, F. G., Lev, M. H., González, R., & Henson, J. W. (2006) · Neurology · doi:10.1212/01.wnl.0000242894.21705.3c · Cited by 135
Comparison of One-, Two-, and Three-Dimensional Measurements of Childhood Brain Tumors
Warren, K. E., Patronas, N., Aikin, A. A., Albert, P., & Balis, F. M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.18.1401 · Cited by 114
Watling, C., Lee, D. H., Macdonald, D. R., & Cairncross, J. G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1886 · Cited by 106
Self-citationSteroid‐induced CT changes in patients with recurrent malignant glioma
Cairncross, J. G., Macdonald, D. R., Pexman, J. H. W., & Ives, F. J. (1988) · Neurology · doi:10.1212/wnl.38.5.724 · Cited by 100
Self-citationParney, I. F., Kunwar, S., McDermott, M., Berger, M. S., Prados, M. D., Cha, S., Croteau, D. J., Puri, R. K., & Chang, S. M. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.2.0267 · Cited by 91
Self-citationAdvances in magnetic resonance imaging of brain tumours
Rees, J. H. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200312000-00001 · Cited by 91
Central Nervous System Cancers
Brem, S. S., Bierman, P. J., Black, P. M., Brem, H., Chamberlain, M. C., Chiocca, E. A., DeAngelis, L. M., Fenstermaker, R. A., Friedman, A., Gilbert, M. R., et al. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0037 · Cited by 46
Self-citationPost-Surgical Contrast Enhancement Mimicking Residual Brain Tumour
Cairncross, J. G., Pexman, J. H. W., & Rathbone, M. P. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046643 · Cited by 33
Bevacizumab therapy in recurrent high grade glioma: Impact on local control and survival
Narayana, A. S. L., Raza, S., Golfinos, J. G., Johnson, G., Knopp, E., Zagzag, D., Fischer, I., Medabalmi, P., Eagan, P., & Gruber, M. L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.13000 · Cited by 16
Anatomic, Physiologic and Metabolic Imaging in Neuro-Oncology
Chawla, S., Poptani, H., & Melhem, E. R. (2008) · Cancer treatment and research · doi:10.1007/978-0-387-75587-8_1 · Cited by 8
Research works printed but not linked: 9
- 10.3171/jns.1996.84.2.0174 · doi:10.3171/jns.1996.84.2.0174
- 10.1016/j.surneu.2006.04.015 · doi:10.1016/j.surneu.2006.04.015
- 10.1002/ana.410170607 · doi:10.1002/ana.410170607
- 10.1148/radiology.204.3.9280269 · doi:10.1148/radiology.204.3.9280269
- Matheus MG, 2004, Am J Neuroradiol, 25, 1211
- Floeth FW, 2001, Am J Neuroradiol, 22, 1517
- 10.1023/A:1014571900854 · doi:10.1023/a:1014571900854
- 10.1016/j.crad.2006.09.012 · doi:10.1016/j.crad.2006.09.012
- 10.1055/s-0028-1083696 · doi:10.1055/s-0028-1083696
Cited by
3D Slicer as an image computing platform for the Quantitative Imaging Network
Fedorov, A., Beichel, R., Kalpathy-Cramer, J., Finet, J., Fillion-Robin, J.-C., Pujol, S., Bauer, C., Jennings, D., Fennessy, F., Sonka, M., et al. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.05.001 · Cited by 9,023
The multimodal brain tumor image segmentation benchmark (BRATS)
Menze, B. H., Jakab, A., Bauer, S., Kalpathy-Cramer, J., Farahani, K., Kirby, J., Burren, Y., Porz, N., Slotboom, J., Wiest, R., et al. (2015) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2014.2377694 · Cited by 6,781
Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation
Kamnitsas, K., Ledig, C., Newcombe, V. F. J., Simpson, J. P., Kane, A. D., Menon, D. K., Rueckert, D., & Glocker, B. (2017) · Medical Image Analysis · doi:10.1016/j.media.2016.10.004 · Cited by 3,498
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Self-citationEANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Self-citation
Metadata
- Authors
- Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., Tsien, C., Mikkelsen, T., Wong, E. T., Chamberlain, M. C., Stupp, R., Lamborn, K. R., Vogelbaum, M. A., van den Bent, M. J., & Chang, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-10
- Volume
- 28
- Issue
- 11
- Pages
- 1963-1972
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162643152
- Cited by
- 3,836
- References
- 49
- FWCI
- 69.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.